IMM-101
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Other names | Mycobacterium obuense (heat-killed) |
| Identifiers | |
| UNII | |
IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy.[1] It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs.[2][3]
References
- ^ Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, et al. (September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–796. doi:10.1038/bjc.2016.271. PMC 5046215. PMID 27599039.
- ^ Boseley S (6 September 2016). "New drug 'wakes up' immune system to fight one of deadliest cancers". The Guardian.
- ^ Dalgleish V (17 March 2015). "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery". Cancer Research UK.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Articles with short description
- Short description matches Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Experimental cancer drugs
- Chemotherapy
- All stub articles
- Pharmacology stubs